Eugene Yuanjin Rui

This inventor holds 14 USPTO granted patents and 14 published patent applications, plus 5 CIPO patents and 6 EPO patents. Top assignees: Pfizer Corporation, Agouron Pharmaceuticals, Inc.. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eugene Yuanjin Rui. Retrieved from https://idiyas.com/inventor/eugene-yuanjin-rui

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 14)

% Patents Active = 85.7

CIPO Patents = 5 (Patent Applications = 13)

EPO Patents = 6 (Patent Applications = 20)

Average Co-Inventor Count = 8.9

ph-index = 5

Forward Citations = 54(Granted Patents)

Company Filing History:

Agouron Pharmaceuticals, Inc.

patents

Years Active: 2006-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297190 - Modulators of STING (stimulator of interferon genes) (2025-05-13),

2. 11964978 - Modulators of STING (stimulator of interferon genes) (2024-04-23),

3. 11396512 - CDK2/4/6 inhibitors (2022-07-26),

4. 11203594 - Anti-proliferative agents for treating PAH (2021-12-21),

5. 10968242 - Cyclopentane-based modulators of STING (stimulator of interferon genes) (2021-04-06),

6. 10800783 - CDK2/4/6 inhibitors (2020-10-13),

7. 10709709 - Substituted carbonucleoside derivatives useful as anticancer agents (2020-07-14),

8. 10538542 - Cyclopentane-based modulators of STING (stimulator of interferon genes) (2020-01-21),

9. 10428104 - Substituted nucleoside derivatives useful as anticancer agents (2019-10-01),

10. 10246433 - Aryl and heteroaryl fused lactams (2019-04-02),

11. 10220037 - Substituted carbonucleoside derivatives useful as anticancer agents (2019-03-05),

12. 9040515 - Aryl and heteroaryl fused lactams (2015-05-26),

13. 7462713 - Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy (2008-12-09),

14. 7132533 - Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy (2006-11-07),

Title: Innovative Contributions of Eugene Yuanjin Rui

Introduction

Eugene Yuanjin Rui is a prominent inventor based in San Diego, California, recognized for his substantial contributions to the field of biopharmaceuticals. With an impressive portfolio of 14 patents, he has made significant strides in the development of novel compounds, particularly in the realm of immunology.

Latest Patents

Eugene's latest patents focus on modulators of STING (stimulator of interferon genes), showcasing his expertise in the development of compounds that can play a vital role in stimulating immune responses. These patents include detailed descriptions of the general formula for these compounds, the processes for their preparation, and their potential pharmaceutical applications, including compositions containing these compounds and their varied uses.

Career Highlights

Throughout his career, Eugene has worked with renowned companies such as Pfizer Corporation and Agouron Pharmaceuticals, Inc. His tenure at these organizations has allowed him to engage in cutting-edge research and development, driving forward innovations that benefit public health.

Collaborations

Eugene has collaborated with esteemed colleagues in the industry, including Martin James Wythes and Indrawan James McAlpine. Together, they have contributed to the advancement of technologies and compounds that hold promise in the treatment of various diseases, illustrating the value of teamwork in the realm of scientific innovation.

Conclusion

Eugene Yuanjin Rui stands out as a leading figure in biopharmaceutical innovation. His dedication to research and development, along with his collaborative efforts, continues to influence the future of immunotherapy and related fields. With his expanding portfolio of patents, he remains a significant contributor to the scientific community and beyond.

Profile summary based on public USPTO records.